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Background: In the United States certain minority groups, such as racial/ethnic immigrant women, are less likely
than non-Hispanic White women to be screened for cervical cancer. Barriers to such care include health insurance,
cost, knowledge, attitudes, health literacy, and cultural norms and practices. Among the most promising approaches to
increase screening in these groups are patient navigators that can link women to sources of appropriate care. Another
recent promising approach is using human papilloma virus (HPV) self-sampling. In this manuscript, we describe our
National Cancer Institute-sponsored study testing such approaches among immigrant minority women.
Design: The South Florida Center for the Reduction of Cancer Health Disparities (SUCCESS) is conducting a three-arm
randomized trial among Hispanic, Haitian, and African American women in Miami-Dade County. Community health
workers (CHW) based in each of three communities are recruiting 200 women at each site (600 total). Eligibility criteria
include women aged 30–65 years who have not had a Pap smear test in the last 3 years. Prior to randomization, all
women undergo a standardized structured interview. Women randomized to public health outreach, Group 1, receive
culturally tailored educational materials. Women in Group 2 receive an individualized comprehensive cervical cancer
CHW-led education session followed by patient navigation to obtain the Pap smear test at community-based facilities.
Women in Group 3 have the option of navigation to a Pap smear test or performing HPV self-sampling. The primary
outcome is self-report of completed screening through a Pap smear test or HPV self-sampling within 6 months
after enrollment.
Discussion: SUCCESS is one of the first trials testing HPV self-sampling as a screening strategy among underserved
minority women. If successful, HPV self-sampling may be an important option in community outreach programs
aimed at reducing disparities in cervical cancer.
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Cervical cancer disproportionately affects women of color.
In 2010, the cervical cancer incidence rate per 100,000
was 9.8 for Black women and 9.6 for Hispanic women
versus 7.2 for White women [1]. The cervical cancer
mortality per 100,000 women was 3.9 for Blacks and 2.6
for Hispanics versus for 2.1 non-Hispanic women [1]. In
Florida, 67% of Black women presented with cervical
cancer at an advanced stage versus 49% of White
women [2]. Cervical cancer is also a highly preventable
cancer. Cytological screening (Papanicolaou smear or
Pap smear test) among women aged 21 to 65 years every
3 years or for women aged 30 to 65 years substantially
reduces cervical cancer incidence and mortality [3]. With
such enhanced public health promotion efforts, the
vast majority of women in the United States (US) now
have cervical cancer screening at least every 3 years [4].
As a result, since 2000, cervical cancer mortality and
incidence have been decreasing and racial and ethnic
disparities have narrowed [1].
Despite these gains, approximately 50% of cases of
cervical cancer are diagnosed in women who have not
been screened for more than 5 years. Further, not all
women have benefited equally from these gains and
certain groups remain vulnerable. Most at risk are im-
migrant women, including Latinas, Caribbean Blacks,
and certain Asian subgroups. As an example, nationally
among Latina immigrants, 70% had not completed a
Pap smear test in the last 3 years [5]. Haitian women are
particularly vulnerable with only 44% of such women hav-
ing a Pap smear test in the last three 3 years [6]. These
rates are substantially lower than the national cervical
cancer screening rates of 87% [4]. Important risk factors
for not being screened are immigration status, lack of
insurance, length of time in US, language, and low levels
of acculturation [4-6]. Additionally, among some minor-
ity and immigrant groups, socio-cultural perceptions of
health, preferences for non-traditional health modal-
ities, and historical distrust of outsiders also plays a role
in screening disparities [6].
To date, one of the most promising approaches to
increase cancer screening in this population has been
using community health workers (CHWs). CHWs, also
known as lay health workers, are community members
without formal health care education who serve as a
link between patients and providers to promote health
among groups traditionally lacking adequate health care.
A few well designed studies have found that CHWs are
effective at increasing screening rates [7,8]. However,
the absolute increase is modest with an average median
increase of 10 percentage points over baseline screening
rates in the target communities [9].
Thus, there is a need for additional novel strategies
to increase screening in these groups. One promisingapproach builds on the role of detection for the presence
of carcinogenic strains of the human papilloma virus
(HPV) as part of cervical cancer screening [10,11]. Nearly
all cases of cervical cancer are the result of infection with
oncogenic strains of the HPV. Until a few years ago, HPV
detection was primarily used for reflex testing of women
whose Pap smear test results were indeterminate (atypical
cells of unclear significance, i.e., ASCUS). Subsequently, in
2012, the US Preventive Services Task Force (USPSTF)
recommended concomitant use of HPV screening with
Pap smear cytology for cervical cancer screening among
all women. Then, in 2014, an FDA advisory committee
unanimously recommended that the HPV test using poly-
merase chain reaction (PCR) could be used as the initial
test for cervical cancer screening [12].
One particular characteristic of HPV testing that makes
it important as a tool to reach underserved women is that
women can self-collect their own swabs without having to
undergo a traditional pelvic exam. A recent meta-analysis
found that the sensitivity and specificity of self-collected
HPV samples were similar to clinician-collected samples
when samples were analyzed using PCR-based testing and
only slightly lower when using signal amplification-based
assays [13]. Another study among Mexican women showed
that self-testing was as effective as cytology screening even
when scaled up in large populations [14]. Thus, increas-
ingly, HPV self-sampling is being recommended as an
important strategy to reach women not currently being
screened. In the US, studies have also shown the feasi-
bility of this approach as an outreach strategy for under-
served women [15,16]. However, whether this approach
is superior to standard outreach methods, such as pub-
lic health education campaigns or approaches using
CHWs, is unclear.
Objectives
To address this gap in knowledge, our study objective
is to conduct a randomized trial that seeks to examine
the effectiveness of a CHW-led outreach strategy that
includes HPV self-sampling at increasing Pap smear
screening among minority women who are not up to
date on their Pap smear testing. This approach is being
compared to standard public health outreach using
culturally-tailored health education brochures and to a
CHW-led outreach intervention that includes individu-
alized patient navigation to health care facilities provid-
ing low cost screenings.
Methods
Participants, interventions, and outcomes
Overview and trial design
Our study is a randomized controlled trial of 600 women
in three communities in Miami-Dade County (South-Dade,
Little Haiti, and Hialeah). Minority women, aged 30 to 65,
Carrasquillo et al. Trials 2014, 15:299 Page 3 of 11
http://www.trialsjournal.com/content/15/1/299who have not completed a cervical cancer screening in the
past 3 years and who agree to participate in the study
have a 30-minute intake visit by one of our two bilingual
research assistants (RA). Once they complete our re-
search intake survey, they are randomized into one of
three possible interventions. The public health outreach
group receives culturally tailored cervical cancer health
education materials and brochures indicating locations
where low cost Pap smear screening is available (Group 1).
The second group undergoes a comprehensive CHW out-
reach intervention that includes home visits and patient
navigation to help women obtain low cost Pap smear
screening in their community. The third group receives the
comprehensive CHW intervention and the opportunity to
have home HPV self-sampling at the time of visit. The pri-
mary outcome is self-reported cervical cancer screening
(either Pap smear test or via self-sampled HPV screening)
determined at a 6-month follow-up assessment done by a
RA blinded to study allocation.
Conceptual approach
Conceptually, the design of our intervention is theoret-
ically grounded on contemporary models specifically
designed to facilitate the design and understanding of
successful interventions to reduce disparities in health
care among diverse communities [17]. The critical focus
of such approaches is that persons reside within a com-
munity and not as patients in a healthcare system. Thus,
critical for success of an intervention is linking persons in
underserved settings with effective health care delivery.
Equally important in our approach is the use of principles
of community-based participatory research. This strategy
has emerged as one of the most promising frameworks
towards reducing health disparities [18]. In SUCCESS,
our two key community partners are: 1) Health Choice
Network of Florida (HCN), which includes two Federally
Qualified Health Center (FQHCs) systems, and 2) the
Center for Haitian Studies. In the study, these community
partners are full participants in all phases of the project in-
cluding the conception, design, conduct, interpretation of
findings, and dissemination of results. Through several
face-to-face meetings and conference calls, the community
partners had substantial input in the study design includ-
ing: 1) selection of geographic sites, 2) design of the CHW
interventions (recruitment approach, conduct of home
visits), 3) evaluative metrics (inclusion of measures of sat-
isfaction and access to care), 4) ethical issues (all partici-
pants are offered HPV self-sampling at the end of their
study participation), and 5) dissemination strategies (pre-
sentations to their boards, lay summaries in their newslet-
ters). In addition, the intervention is being delivered by
the CHWs, who are hired and based in these organiza-
tions rather than at the academic health center. Nearly
half the research budget is allocated to these partners.Study setting
For the study, the target communities we chose reflect
the ethnic diversity in Miami-Dade. One is Little Haiti;
Florida is home to more than a third of all Haitians in
the US and Miami has the highest concentration of
Haitians in the state. Little Haiti, in the northern section
of Miami, has an estimated 200,000 Haitians. Most are
recent immigrants who are low income, have limited
formal education, and restricted access to the formal
healthcare system. In addition, given their double mi-
nority status (Black and Kreyol speaking), the integra-
tion of Haitians is often slower and more challenging
than that of other immigrant groups. In Little Haiti, we
are working with the Center for Haitian Studies, one of
the community’s leading social service organizations,
which also operates a community-based healthcare facility.
Our second community is Hialeah which is a separate city
within Miami-Dade County. This city includes over
200,000 residents of which 94% self-identify as Hispanic
and 62% of which are Cuban. As suggested by HCN, in
Hialeah, we are working with Citrus Health Network Inc.,
the largest FQHC in Hialeah. The third target area is the
southern portion of Miami-Dade county (South-Dade)
which is much less urban than the above two communi-
ties. This is a very mixed landscape, including areas closer
to the city composed of large low-rise public housing
complexes, factory and industrial warehouses, and further
out more rural agricultural areas with a large proportion
of migrant farm workers. The area is also very ethnically
diverse including large multi-ethnic enclaves of Latinos
and Blacks, including some Haitians. In this commu-
nity, we are working with Community Health of South
Florida Inc. This is a FQHC network that includes
several facilities and serves as the major provider of
healthcare services to medically indigent residents in
southern Miami-Dade County.
In each community, we are working with community
advisory boards (CABs) composed of residents who rep-
resent organizations focused on health issues and socio-
economic services. The CABs also include individuals
who are cancer survivors and relatives or friends of per-
sons who have been stricken with cancer. The CABs
meet approximately every two months and these groups
have been influential in identifying strategies for recruit-
ment of study participants.
Eligibility criteria
Inclusion criteria
To be eligible, women must be living in one of the
three target communities and self-identify as Haitian,
Hispanic, and/or Black. They must be aged 30 to
65 years old and not have had had a Pap smear test in
the last 3 years. Women under 30 years of age have a
high false positive HPV rate due to transient HPV
Carrasquillo et al. Trials 2014, 15:299 Page 4 of 11
http://www.trialsjournal.com/content/15/1/299infections. Thus, the HPV test is not recommended for
women under 30 years old.
Exclusion criteria
A woman is not eligible to participate in the study if she i)
reports having had a hysterectomy, ii) has a history of
cervical cancer, iii) plans to move out of the neighborhood
during the next 6 months, or iv) is currently enrolled in
any other cancer prevention/outreach related study.
Intervention
The CHWs
In all three arms of our study, participants are initially
identified for participation and receive the intervention
with the assistance of our three study CHWs. All three
CHWs in the project had some experience as outreach
workers but did not have any formalized health care
degrees or training. All of the CHWs reflect the ethnic
and racial representation of their assigned community:
two are Hispanic and one is Haitian. They completed
two weeks of training using modules that covered core
CHW competencies [19,20], cancer education and out-
reach [21], cervical cancer and HPV, and cancer clin-
ical trials [22]. They also completed the University of
Miami-required courses on human subject protections
and HIPAA training using the Collaborative Institu-
tional Training Initiative [23].
Intervention Group 1 – Public health community outreach
As part of our overall efforts aimed at reducing cervical
cancer disparities, CHWs in each targeted community
have been engaged in public health outreach. These
activities include cervical cancer education campaigns
over local ethnic radio stations and articles in local
ethnic newspapers. The CHWs have also developed
health education materials, such as brochures and fact
sheets, which they distribute at events such as health
fairs, community events, and other such gatherings.
These are primarily based on existing materials from
the National Cancer Institute (NCI) as well as other
sources, such as the American Cancer Society. With
feedback and suggestions from our CABs and health
educators, these materials are tailored and adopted to
the local culture, characteristics, and language of each
community. The materials include information about
the Pap smear test, why it is important, existing health-
care sources in each community, and how to go about
making appointments for a Pap smear. In our study,
women randomized to Group 1 are given copies of these
brochures at the end of the initial intake visit. They are
told the material has information on cervical cancer
screening and they are encouraged to read the material.
At 3 months these women also receive a brief phone call
for continuity and retentions purposes reminding them ofthe study, obtaining any updated contact information and
reminding them that at 6 months they will be called to
schedule a follow-up visit by the RA.
Intervention Group 2 – CHW individualized health
education and patient navigation
Each participant randomized to this arm receives a one-
to-one health education session of approximately 1 hour.
If randomized to this group, CHWs contact participants
to schedule the session at a mutually convenient location.
With input from professionally trained health educators
and our clinical partners, the study group developed an
evidence-based implementation guide as a model for con-
ducting one-to-one health education sessions. The inter-
vention strategies involve three overlapping domains: i)
health education on cervical cancer screening, ii) motiv-
ation to encourage women to complete screening, and iii)
navigation to access screening services. Study guidelines
emphasize the importance of CHW judgment as to con-
tent and delivery to tailor the approach for each woman
and her unique circumstances. The session begins with
introductory comments followed by probing question to
help individualize the intervention. Probing questions
begin with generalized inquiries about what each woman
knows about Pap smear tests to more targeted items ask-
ing about reasons for not having Pap tests. Based on the
answers, the CHW decides how to target the intervention
strategy. The CHW guide also suggests courses of action
based on potential participant responses for each to con-
sider as examples. For some women, the CHWs may need
to spend time providing basic health education including
explaining basic anatomy and concepts about cancer and
screening, such as the relationship of early detection to re-
ducing cancer-related mortality. For others, the discussion
may also include an expanded discussion of the relation-
ship of HPV to cervical cancer risk. This is facilitated with
education materials the CHW adapts from our existing
materials or other NCI resources, including anatomical
graphics, brochures, and flipcharts.
Navigation
In addition to health education, a major role for the
CHW is to offer women practical assistance that would
facilitate her access to screening services. Navigation
services may range from explanation of services offered
at our participating clinical sites, availability of sliding
fees and specific programs for cervical cancer screening
for the uninsured (such as the Center for Disease Con-
trol early detection breast and cervical cancer screening
programs), and assistance with making/scheduling the
clinical appointments for the participant. On a case by
case level, CHWs may provide assistance with other issues
such as transportation (bus routes), potential language,
cultural, or even child care issues, and, if requested,
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also make appointment reminder calls the day prior.
Within 2 weeks after a woman has the Pap smear
screening, CHWs will contact the participant by phone
to see if she requires any further assistance. If patients
have not been notified of the results, with patient con-
sent, the CHW tries to obtain the information from the
FQHC and, with provider approval, may relay findings
to the patients (all sites use electronic records). CHWs also
play an important role by ensuring that each woman un-
derstands her test results. She may also provide further
navigation by assisting with additional follow-up as needed,
such as for colposcopy (available at each of our sites).
Intervention Group 3: HPV self-sampling option
Women randomized to this arm receive the same health
education session as Group 2. In addition, the education
includes information on HPV self-sampling as an alter-
native screening method. They receive an offer of choos-
ing between the HPV screening at the conclusion of the
educational session or navigation services to a traditional
Pap smear test at a local healthcare facility. If the woman
chooses the HPV self-sampling strategy, the CHW pro-
vides detailed instructions to complete the sample col-
lection. Using standardized operating procedures and
study-specific visual aids and flipcharts we developed,
they teach women the proper self-sampling collection
technique. Women complete the test in a bathroom
while the CHWs wait outside to answer any questions
that may arise during the process.
We are using the HPV self-sampling device developed
by Preventive Oncology International and the National
Institutes of Health, which is a nylon swab 2 cm in
diameter and 15 cm in length. Based on prior feedback
on comfort and ease of use from earlier study partici-
pants, we are using the sampler without the outer
sheath. After the woman collects the sample using the
swab, she removes the swab out of her vagina and gives it
to the CHW. The CHW puts the swab in a pre-labeled
liquid media vial (ThinPrep, Holigic Inc., Bedford, MA,
US) stirs the sample, caps the bottle, and stores the
sample in a re-sealable plastic bag in a locked cabinet.
Once a week, the CHW delivers the samples to the
University of Miami’s Department of Pathology for pro-
cessing. The sample is then sent to an outside CLIA
approved laboratory (Quest Diagnostics Inc.) for HPV
testing. Initially our specimens were being processed by
Quest using the Cervista HPV Invader Assay (Holigic
In.) [24]. This was later changed to APTIMA HPV
Assay (GenProbe Inc.). The former tests for HPV using a
DNA based two-step signal amplification method and the
latter tests for mRNA using a three step transcription-
mediated amplification assay [25]. Both assays test for the
14 HPV strains which have been identified as high riskHPV by the International Agency for Research on Cancer
[26] (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
68). They have similar sensitivities for detection of cervical
intra-epithelial neoplasia (CIN2+) [27].
After the specimen is collected, the CHW asks the
woman a few additional questions concerning her ex-
perience with the procedure, including ease of use,
perceived correctness of device use, degree of pain
associated with use, and willingness to recommend
the device to family or friends as an alternative to Pap
smear testing. The CHW also stresses the importance
of seeing a health care provider to address any other
health issues she identified during their conversations.
The CHW also advises the woman that a positive
result (i.e., positive for HPV high risk), will require
follow-up up to ensure she receives recommended
medical care. In rare cases where a submitted sample
is deemed as quantity not sufficient by the laboratory,
CHW will ask the woman to undergo a second HPV
sampling.
Primary outcome
The primary outcome is self-report of completion of a Pap
smear or HPV test since the initial evaluation. We will
assume that women who were lost to follow-up (no
further contact) did not complete a cervical cancer
screening. However, participants successfully contacted by
phone but who declined in-person follow-up evaluation
are asked if they completed a Pap smear or HPV test. Data
obtained from this phone call will be included in a sen-
sitivity analysis on our primary outcome.
Secondary outcomes
There will be two secondary outcomes. The first is cervical
cancer knowledge. Women in Groups 2 and 3 receive
a 1-hour health education session. Thus, changes in
cervical cancer knowledge from baseline to follow-up
will be compared across the three groups. For each
woman, the change in proportion of questions an-
swered correctly will be examined.
The other secondary outcome will be access to care.
Although improving access to care is not specifically
part of the intervention, conceptually, a major role for
CHWs is linking women in their communities to health
care. Thus, as a secondary outcome we will determine
the impact of our CHW intervention at improving
access to healthcare. This will include an analysis of
survey questions regarding having health insurance, a
usual source of preventive care, and number of visits
to a provider within the last year. By including this as a
secondary outcome, it will help us examine whether
access to care improved among participants having a
CHW. This data will also help to address concerns that
women in Group 3 who receive negative results from
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and do not need to see a health care provider. That is,
it will allow us to examine whether access among par-
ticipants in Group 3 remained the same as those in
Group 2.
Sample size
In the study, we are recruiting 600 women from three
study sites. The sample size was chosen to detect effects
associated with a 20 point increase in the proportion of
women screened in Group 2 (CHW) versus Group 1
(outreach) and an additional 15 percentage point in-
crease in Group 3 (HPV self-sampling) versus Group 2.
In addition, as women are randomized within each site,
sample size calculations were adjusted to account for
clustering of patients within each community. Based on
these parameters, we examined power estimates under a
variety of assumptions for attrition with estimates ran-
ging from 0% to 30%. As shown in Figure 1, with a total
sample size of 600 women (200 women in community),
we will have sufficient power for the main study hypoth-
eses, under a variety of attrition rate assumptions at a
0.05 level of significance.
Participant timeline
At each of the three sites we are recruiting 200 women
over a 40-month period with a target of six women per
month at each site for a total of 20 women per month.
At 6 months following enrollment, we will conduct a
follow-up survey to determine if women completed
screening for cervical cancer. Participation ends after
this 6-month interview.
Recruitment
Three CHWs based at the three clinical sites located in
our target communities are leading the recruitment
effort. With input from local CABs, field supervisors, and
University of Miami study team staff, and using tech-
niques such as community mapping, each CHW devises
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such as laundromats, pharmacies, hair salons, flea mar-
kets, social service sites (WIC centers), libraries, churches,
and community colleges. Other strategies include inform-
ing the community about the study through radio stations
serving ethnic listeners, free community service advertis-
ings in local newspapers, as well as flyers and posters.
Once women are identified through these outreach strat-
egies, the CHWs screen them for potential eligibility. We
collect de-identified data from all assessments to track
the number of women approached by the CHWs and
the proportion who were not study eligible due to
reasons such as age or having a Pap smear test within
the last 3 years. Among those women who have not had
a Pap smear, CHWs ask additional questions addressing
the inclusion and exclusion criteria. For those women
who are potentially eligible, the CHWs describe the
study in further detail. If a woman expressed potential
interest, we assign a study ID and collect two contact
numbers and follow-up with phone calls to arrange a
mutually convenient time and location to conduct an
intake interview. CHWs make up to 10 attempts to reach
each woman. Ideally, the intake visit takes place within
4 weeks of the initial contact. The CHW and RA complete
two appointment reminder calls prior to the visit.
Methods: data collection, assignment of intervention, and
analysis
Data collection methods: study intake visit
The study intake visit takes place in an area of mutual
agreement with the woman. The intake visit most often
occurs in the woman’s home or the local health center
but may also take place in other locations. During the
intake visit, the RA completes another inclusion screening
to verify that the woman meets the study criteria. The
study is again explained to the woman and any questions
answered. After the woman signs the informed consent
form, the RA then proceeds with the structured interview.
Based on community input, brevity was the overarching
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more than 30 minutes. In Table 1, we list the questions
and instruments used in our intake survey. At the
conclusion of the intake visit, the RA thanks the woman
for her participation in the study and gives her a study
business card and a $25 store gift card to cover their
time and effort for participation in the study. The RA
tells her to expect a call within a week from the CHW
to identify her assigned study group. The RA also
reminds the woman that at 6 months there will be a
follow-up interview.
Data management
After discussion with some of our community partners
and advisory groups, it was felt that collection of data
using pen and paper would be more acceptable to the
target population than using computer tablets. Thus, we
are using paper surveys to collect data which is then
input into a Microsoft Access relational study database
by a data manager. Initially, all survey entries were
double checked for accuracy by a RA and since then
every 10th survey is being double checked. Data is also
periodically checked by the study statistician for values
that are missing, out of range, and for other inconsist-
encies. As needed, these values are discussed with the
study team who then decide how to proceed based on
the cause.
Allocation and blinding
Once women complete the intake questionnaire they
are randomized into one of three possible interventions
by the study coordinator who has the pre-generated
randomization list from the study statistician. As the
study design is hierarchical, with each participant nested
within a site, the randomization is based at the site level.
A study coordinator notifies the CHW assigned to that
woman of the group assignment, and the CHW then
follows-up with the women within a week, informing
them of their assignment. If women are randomized to
Groups 2 or 3, a follow-up visit is scheduled, ideally no
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assessment is blinded to study allocation. However, both
women and CHWs are aware of the group to which
each participant was randomized.
Follow-up evaluation at 6-months
At 6 months, a RA blinded to study group allocation
does a 6-month follow-up evaluation. The visit takes
place in an area of mutual agreement with the woman.
Up to 10 phone calls are made to the patient at different
times and days, including weekends, to try to contact
them to schedule the appointment. If the participant
cannot be reached, attempts will be made using the
other contact information that was provided during
study intake or follow-up phone calls. If after 2 months
the RA has been unable to schedule the appointment, in
most cases, participants will be considered as lost to
follow-up. However, in some cases the interval may be
extended. This may occur if, for example, a participant
was out of the country for a few months but had
planned to return.
Statistical analysis
All data will be analyzed using the intent-to-treat
principle and we assume that women who were lost to
6-month follow-up did not have any screening. Initially,
we will perform an explanatory data analysis; visually via
graphics/plots, such as scatter and box-whisker plots,
and numerically by descriptive statistics, such as range,
median, means, and standard deviations, for measure-
ments taken on a continuous scale. Percentages and
various types of cross-tabulations will be performed for
measurements taken on a categorical scale. Correspond-
ing confidence intervals for means and proportions will
also be calculated. To have a better understanding of the
relationships among different study measurements, para-
metric or non-parametric correlation coefficients, bivari-
ate, and multidimensional cross-tabulations, scatter, and
box-whisker plots will be constructed. Prior to analyses,
baseline differences of key covariates from each arm will
be examined with respect to our primary outcome,estions/Instruments used
e, race/ethnicity, education, income marital status, and citizenship status
rin-Marin scale [28]
HL-S&E [28] (only asked if person are fluent in English or Spanish); not
ailable in Kryeol thus they are only asked if they can read
estions from Center for Disease Control National Health Interview Survey
cess to Care module
estions from the NCI’s Health Information National Trends Survey (HINTS) [28]
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will also examine differences on key variables between
participants who completed the study and lost-to-follow-
up. Analysis of variance for differences in means and χ2
test for difference in proportions will be used to test the
differences among the three study arms. Several univariate
and multivariate logistic regression models will be used to
calculate odds ratios and corresponding 95% confidence
intervals for exploring the result of having had Pap smear
screening and the relationship to various types of key
study covariates. Two-way interaction terms between
various study variables and the study arms will also be
included in the models. Standard diagnostic tools will
be used to assess model fit. Transformations of the
continuous data in order to meet statistical assumptions
will be undertaken when indicated. We will treat pri-
mary and secondary outcomes as separate clusters,
setting a 0.05 level of significance to the primary out-
come. A Bonferroni correction will be applied to sec-
ondary outcomes. All statistical analyses will be carried
out using SAS® version 9.3 or later for Windows (Cary,
NC, US) and/or the R project for Statistical Computing
for Windows (http://www.r-project.org/).
Subgroup analysis
Planned subgroup analyses include examining whether
the intervention was more efficacious among women in
one community versus another. We will also examine
if there was a differential impact of the intervention
among women who had lower education, lower accul-
turation level or had lower levels of baseline cervical
cancer knowledge. In addition we will also examine if
there was a difference among the groups in awareness
of their results and among those told of abnormal find-
ings (Pap or HPV), the proportion having had appro-
priate follow-up testing. We will consider all these to
be hypothesis-generating analysis and not definitive
since we will lack statistical power for most of these
subgroup analyses.
Cost analyses
Although the study does not include a formal cost
effectiveness analysis, we will provide estimates of the
cost of screening an individual woman in the each of
the intervention arms. To calculate a total cost for each
group we will assess the resources that were used in the
project. This will include all personnel time, including
personnel time devoted to training the RAs and CHWs,
RA and CHW time (e.g., time spent assessing eligibility,
managing contacts, recruiting, conducting the inter-
vention, and administrative time), and resources used
such as space, supplies, and medical care. For each of
the different types of resource utilization, including
personnel time, we will establish a standardized pricefor a unit of that resource. The cost of the medical care
categories will be obtained by either i) the actual cost
(e.g., for analyzing the self-samplers) or ii) the average
cost of Pap smears at the clinics where testing was
done. Total costs for each activity or supply will be
calculated by multiplying the units used by the stan-
dardized “price”. Costs that are not attributable to a
single arm, such as personnel time for training the
CHW and RA, will be divided equally among the three
arms of the project, or allocated as best estimated by
resource use intensity of each arm. Total costs for each
of these arms will be calculated using the information
on resource utilization and standardized prices. Then
an average cost per participant, and per woman
screened, for each group can be obtained. From know-
ing the cost per woman screened in each arm, we can
determine the additional cost of screening additional
woman in Groups 2 and 3 as compared to the group
simply receiving public health outreach.
Data monitoring
The NCI expressed high interest in having semi-annual
data with respect to our primary outcome as the study
was progressing. Thus, interim analyses are being per-
formed every 6 months on our primary outcome and
reported back to the NCI. As part of a data safety mon-
itoring plan, at monthly study team meetings attended
by all research study staff, the RA and CHWs present
any adverse events that resulted from study participa-
tion as well complaints by participants and any other
unanticipated harms and unintended effects of partici-
pating in the study. In addition, our quality control
activities include monitoring of recruitment (weekly,
using standard reports), monitoring the eligibility of
enrolled participants, and periodic audit of consent
forms to insure signatures and properly filed consents
for all enrolled participants.
Ethics and dissemination
Protocol approvals and amendments
The study was approved by the University of Miami
Institutional Review Board, initial approval date on 12/
22/2010, protocol #20100834. Since then, there have
been eight approvals for minor amendments to the
study protocol, most of which involve adding study
personnel to the research team.
Consent
Informed consent is being obtained by our two bilingual
RAs (Spanish/English, Haitian Kreyol/English) prior to
the baseline intake. The women are given the informed
consent form in their preferred language which they
read and review along with the RA. If the woman states
that she cannot read or if the CHWs suspects that the
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tion in the consent form is read aloud to them. Once all
questions have been answered, the woman is asked to
sign the informed consent form. For women who cannot
read, a witness signs indicating the form was read to the
participant.
Confidentiality
To maintain participant confidentiality, study specific ID
codes are used in all study tracking and analyses. Only
the CHWs and project coordinator have access to the
files linking participants with study ID numbers. These
password protected files are stored in password pro-
tected computers. All paper surveys only have study ID
numbers without names. These are stored in locked
cabinets in locked offices.
Financial interests
None of the study team members, including the princi-
pal investigators, have any financial or other competing
interests in the study.
Access to data
Only the study statistician has access to the raw data
files entered by the data manager. Data files that have
been cleaned and appropriately grouped and categorized
will be made available to study personnel requesting
such data. This includes the principal investigators,
project coordinators, and our community partners. The
statisticians will also make preliminary charts and tables
when requested by study team members. Outside groups
interested in access to the data will be granted access to
limited datasets after submitting such requests to the
study principal investigators.
Post-trial care
Ensuring that at the conclusion of the study all unscreened
women are offered recommended screening was an im-
portant ethical consideration made by our community
partners. Thus, once the study-related follow-up data has
been collected, the CHWs will offer HPV testing to all
women who have not been screened. For unscreened
women declining the HPV testing, the CHWs will also
offer their assistance in making appointments for Pap
smears. For tracking purposes, we will also collect data on
HPV outcomes among these women.
Dissemination policy
Our study findings will be presented at scientific meet-
ings and published in peer reviewed journals. Based on
our community-based participatory research framework,
the active role of the community partners is such that
we have agreed to have at least two partners play a key
role in drafting each manuscript that will be publishedfrom this research effort and appropriately include them
as authors in all such manuscripts. The NCI will also re-
ceive copies of our final results in our final report. Find-
ings will also be reported in http://clinicaltrials.gov/. In
addition, we will also present our results to community
advisory boards we established in each community. We
will also disseminate our findings to community mem-
bers, patients, and other stakeholders, as well as in
public forums, presentations to their boards, and lay
summaries in the newsletters and ethnic media such as
radio and television in all three languages (Spanish,
Kryol, and English).
Discussion
Minority immigrant women (both Hispanics and Blacks
from Haiti) are less likely to be screened for cervical
cancer than the general population. In this research
project of the South Florida Center for the Reduction of
Cancer Health Disparities (SUCCESS) we are conduct-
ing a randomized study on cervical cancer screening
among 600 women in three underserved communities
in Miami-Dade County. Data from this study will allow
us to determine optimal approaches to increase cervical
cancer screening among underserved women in our
community. It will compare screening through standard
public health outreach versus CHW-assisted patient
navigation and a CHW intervention that includes the
option for HPV self-sampling.
One methodological concern relates to our study
design in which we have assigned one CHW to each com-
munity. As a result, the differences observed across differ-
ent communities may reflect the impact of the CHW and
not the intervention itself. Process data such phone calls,
time with each participant, and follow-up will allow us to
examine service intensity and examine if the intensity of
the intervention varied in each community. In addition,
as both groups two and three involve delivery of similar
educational content, as a fidelity check of the CHW
intervention we can examine differential changes in cer-
vical cancer knowledge across the three sites. If present,
such variations, may suggest differences in the CHW
delivery of the intervention.
A second important methodological concern is that
our primary outcome is a self-reported Pap smear, which
is the approach used to track cervical cancer screening
in national surveys such as the Behavioral Risk Factor
Surveillance System and National Health Interview
Survey. However, self-reports are a subjective measure
and prior studies suggest that when initially asked about
cervical cancer screening using self-reports, women may
overestimate having a Pap smear by nearly 30 percentage
points [29,30]. However, those studies focused on women
initially being asked and not those being assessed on
a follow-up evaluation. For our study, we prioritized
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initially and at 6-month follow-up. Further, in our study,
women had many options where to obtain a Pap smear.
These included FQHCs, public hospitals clinics, free
clinics, Center for Disease Control-funded programs,
and private providers. Obtaining access and querying
the electronic medical records or manual chart review
in each of these providers systems would have been ad-
ministratively challenging. For these reason, we opted
self-report as our primary outcome.
An additional concern relates to the evidence in
support of HPV screening. Although HPV detection is
gaining increased acceptance as a primary screening
strategy, self-sampling has still not received full en-
dorsement from the USPSTF. Instead, self-sampling is
recommended as an option to be considered in hard-
to-reach populations [28]. Having underserved women
be screened through an intervention that has not been
fully endorsed by the USPSTF raises issues of social
justice and access to care inequities. The Affordable
Care Act is an important step in helping improve
access to care among many women. However, some
low-income women residing in states that have opted
not to expand Medicaid, such as Florida, and women
who are undocumented will not benefit from the
Affordable Care Act insurance expansions. Until all
women have equitable access to care, the approach we
propose is preferable to not having women screened.
Additionally, our group continues to explore other
approaches to expand cervical cancer screening. For
example, we recently obtained an award from the
National Cancer Institute to examine if HPV self-sampling
kits distributed by CHWs at health fairs and mailed back
are an effective screening option. Contributing towards
the science of ensuring all women receive adequate
cancer screening is an important contribution our
SUCCESS center is making towards reducing and ultim-
ately eliminating cancer inequities.
Trial status
As of May 9, 2014, we have enrolled 582 of our target 600
women into the study.
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